Redeye gives a short comment on the Q2 report. We are encouraged by the reiteration of previously communicated timelines and so far, the impact from Covid-19 seems limited. The much-improved cash position from this summer’s share issues (net proceeds of close to SEK 600m) supports BioInvent’s transition into a clinical stage immune-oncology player with a broad pipeline. Our base case of SEK 2.8 stands.